病窦综合征是危害人类健康的常见病，虽然起搏器治疗已获得很大成功，但目前仍有诸多缺陷，缺乏理想、有效的药物治疗。生物起搏是目前研究热点，但机制尚不清楚。基于对 HCN4通道基因在心脏起搏中的作用机制，本课题以慢病毒载体修饰HCN4基因转染骨髓间充质干细胞技术为平台，结合细胞膜片钳技术、westren-blot、RT-PCR 等技术，对骨髓间充质干细胞重建窦房结起搏功能的作用及其机制进行研究。参附注射液治疗病窦综合征在临床上取得良好疗效，我们的前期研究发现参附注射液具有改善损伤窦房结起搏功能的作用，同时观察到其可能机制与提高HCN4基因表达有关。本课题将从HCN4通道基因角度，对参附注射液动员骨髓间充质干细胞重建窦房结起搏功能进行作用机制研究，发掘病窦综合征的治疗靶点及有效药物，为病窦综合征的防治探索一条新的思路和途径。

Sick sinus syndrome(SSS) is a frequent clinical syndrome, which have a great health hazards to human. Although there has been a great success in implantation of permanent artificial electric cardiac pacemaker，there are still many defects,lack of good, effective drug treatment.Biological pacemaker is a hot topic,but the mechanism remains unclear.Here we study the ability of mesenchymalstemcells(MSCs)as delivery platforms which have been loaded with specific genes to reconstruct biological pacemaking function in vitro and in vivo experiments，combining with cell patch-clamp technique, western-blot, RT-PCR techniques，based on the mechanism of HCN4 channel genes in the pacing function.Shenfu Injection has a good clinical efficacy on SSS.Our previous study found that Shenfu Inject can improve injured sinus node pacemaker function,and its mechanism may increase HCN4 gene expression to some extent.This study will focus on the mechanisms of Shenfu Inject mobilizing bone marrow mesenchymal stem cells to reconstruct the sinus node pacemaker function from the perspective of HCN4 gene family,discovering therapeutic targets and effective drugs of SSS,strengthening the efficacy of the mechanism of traditional Chinese medicine,exploring a new way of prevention and treatment of sick sinus syndrome.